Fritextsökning
Artiklar per år
Innehållstyper
-
Hansa Biopharma secures billion deal: “Profitability within reach”
Lund-based Hansa Biopharma is raising more than SEK 1bn through a new licensing agreement for its in-house developed transplant drug imlifidase.
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
GSK eyes blockbuster potential – plans five new trials
GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced and hard-to-treat gynaecological cancers.
-
Diamyd Medical fyller på kassan och slutför rekrytering i fas III-studie
Diabetesforskningsbolaget Diamyd Medical har genomfört en riktad emission av cirka 17,2 miljoner B-aktier till kursen 13,54 kronor och tillförs därmed cirka 233 miljoner kronor före kostnader.
-
Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”
The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a range of neurological diseases, according to Samuel Lagercrantz.
-
Multicancer test failed to meet its goal – shares plunged
A blood test designed to detect multiple types of cancer failed to meet its primary endpoint in a large UK study. The company behind the test saw its market value cut in half.
-
Top 10 biggest drug launches 2026
Two presumed sales rockets – both in obesity and type 2 diabetes – top a list of potential blockbusters expected to launch in the United States in 2026.
-
“The US matters most – even in times of turbulence”
Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and faster support to understand what actually applies. That is the view of Johan Chun, newly appointed Head of Industry at Business Sweden.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
BREAKING